Indications for hyperthermic perfusion therapy:

1. Clinically used for patients with digestive tract tumors, such as gastric cancer and colorectal cancer. During surgery, it is found that the tumor may have partially broken through the outermost serosal layer of the digestive tract, but has not formed intra-abdominal metastasis. In this case, there is an indication for hyperthermic perfusion chemotherapy.

2. Patients with distant intra-abdominal metastasis, such as those with implanted metastases in the abdominal wall, peritoneum, mesentery, or greater omentum, can undergo hyperthermic perfusion chemotherapy after sufficient tumor reduction of the metastatic lesions. This can reduce the rate of tumor progression. Some patients may even develop a large amount of ascites due to intra-abdominal metastasis. Hyperthermic perfusion therapy can effectively control ascites in some patients.

3. The biggest problem with gynecological tumors such as ovarian cancer is that patients with advanced ovarian cancer will develop a large amount of ascites. After removing both ovaries, the patients will receive intraperitoneal hyperthermic perfusion chemotherapy, and the ascites in a considerable number of patients will be better controlled.

The advantages of hyperthermia perfusion therapy are mainly reflected in the following points:

Through the use of hot perfusion therapy drugs and 42℃-45℃ thermal cycling, the growth of tumor cells is effectively inhibited. Because there is a peritoneal barrier in our abdominal cavity, the thermal cycling changes the osmotic pressure and permeability of the cells, allowing chemotherapy drugs to effectively enter the cells and kill cancer cells.

Intraperitoneal hyperthermia is absorbed and circulated primarily through the portal vein into the liver. Peritoneal tumors metastasize primarily through the portal vein, then through the liver and throughout the body. Hyperthermia perfusion chemotherapy also follows this pathway, effectively preventing tumor metastasis and offering a promising treatment option.